Drug Approval | September 09, 2021
Merck’s KEYTRUDA receives China approval for Esophageal cancer
The medicine is now approved for eight indications across five different types of cancer in China.
The medicine is now approved for eight indications across five different types of cancer in China.
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
A veteran in cell therapy and oncology commercialisation
Subscribe To Our Newsletter & Stay Updated
